DBV Technologies Share: 1.5% Rebound After Nearly 35% Decline in Three Months
The Châtillon biotech firm regains some ground at midday, in an SBF 120 oriented upward. This rebound comes after a long series of declines, while the file submitted to the FDA at the end of September has not altered the trajectory of the share price.
A Share Still Far From Its Moving Averages
The DBV Technologies share gains 1.45% to €1.88, against €1.86 the previous day. This gain remains modest given the decline of 9.12% over one week and nearly 35% over three months. The price is trading below its 20-day moving average (€2.11, a gap of 10.76%), as well as below its 200-day moving average at €3.08, representing a gap of 38.86%.
It stands slightly above the €1.86 support level, which the share has been testing for several sessions. The RSI at 32 is close to the oversold zone, which alone does not indicate a reversal.
Short Positions Increasing Despite American Regulatory Progress
The submission of the biological license application to the FDA for the anti-peanut patch, announced on September 30, had triggered a rebound on the same day, which was erased the following day. According to the statements consulted, four funds hold 4.28% of capital in net short positions, compared to 3.64% thirty days ago, an increase of 0.64 percentage points. This rise shows that institutional investors remain positioned downward on the stock, without being able to infer their motivations.
When publishing the H1 2026 results on July 16, the company indicated sufficient cash until the third quarter of 2027, with no revenue at this stage. Its next regulatory milestone is the examination of its file by the FDA.